Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Gd-DOTA-ob5
- Development stage
- Unknown
- Lead developer
- Korea Institute of Radiological and Medical Sciences
- Modality
- MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
Gd-DOTA-ob5 is a novel MRI contrast agent specifically designed to target and visualize oligomeric amyloid-beta (oAβ) deposits in the brain for early diagnosis and research in Alzheimer’s disease. It consists of a gadolinium (Gd)-dodecane tetraacetic acid (DOTA) chelate covalently attached to a DNA aptamer called ob5, which was developed using SELEX to bind with high specificity and affinity to oAβ, a key pathogenic species implicated in early-stage Alzheimer’s disease. Unlike conventional gadolinium-based contrast agents, Gd-DOTA-ob5 selectively accumulates at sites with oAβ, enhancing T1-weighted MRI signals in animal models of Alzheimer’s disease. Its development aims to facilitate early, non-invasive detection and monitoring of oAβ pathology, and enable evaluation of therapeutic interventions in preclinical models[1][2][4].
- Other names
- GdDOTA-ob5GdDOTA-ob-5GdDOTA-ob 5GdDOTA-ob5-cy5GdDOTA-ob-5-cy5GdDOTA-ob 5-cy5
02
Targets
Aβ (Amyloid-beta peptides and aggregates)
Beyond the preview
Go deeper on Gd-DOTA-ob5.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Gd-DOTA-ob5.